APPENDIX 6: DETAILS OF DATA POINTS

The source of all data points in the main analyses of BCG, DTP and measles vaccine against no vaccine is provided in the first column of the tables in Annex C.

This appendix provides the source of the data points in the remaining plots.

1 BCG: ESTIMATES STRATIFIED BY SEX

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
Burkina Faso	#799	Boys	Risk Ratio (adjusted)	0.42	0.23	0.77	Extracted from Table 4
		Girls	Risk Ratio (adjusted)	0.58	0.34	0.98	Extracted from Table 4
Guinea-Bissau A	#166	Boys	MRR (adjusted)	0.59	0.32	1.11	Extracted from page 248
		Girls	MRR (adjusted)	0.51	0.25	1.06	Extracted from page 248
Guinea-Bissau D	#9466	Boys	Risk Ratio (adjusted)	0.63	0.38	1.04	Extracted from page 1
		Girls	Risk Ratio (adjusted)	0.45	0.23	0.86	Extracted from page 1
Guinea-Bissau I	#839	Boys	Risk Ratio (adjusted)	0.11	0.02	0.57	Extracted from page 548
		Girls	Risk Ratio (adjusted)	0.24	0.06	0.91	Extracted from page 548
India A	#741	Boys	Hazard Ratio (unadjusted)	0.57	0.33	0.98	Extracted from Table 4J
		Girls	Hazard Ratio (unadjusted)	0.38	0.2	0.73	Extracted from Table 4K
India G	#9463	Boys	MRR (unadjusted)	0.09	0.05	0.15	Computed from rates on Table 3 (BCG exposed group vs. No vaccination received at 0-5 weeks)
		Girls	MRR (unadjusted)	0.15	0.1	0.23	Computed from rates on Table 3 (BCG exposed group vs. No vaccination received at 0-5 weeks)
Malawi	#664	Boys	MRR (adjusted)	0.44	0.13	1.44	Extracted from Table 2B
		Girls	MRR (adjusted)	0.4	0.07	2.15	Extracted from Table 2B
Papua New Guinea	#784	Boys	MRR (unadjusted)	0.21	0.1	0.45	Computed from Table 3 (BCG only-Male vs. No BCG or DTP-Male at 29 days-5 months)
		Girls	MRR (unadjusted)	0.11	0.04	0.3	Computed from Table 3 (BCG only-Female vs. No BCG or DTP-Female at 29 days-5 months)
Senegal D	#9433	Boys	MRR (unadjusted)	0.92	0.41	2.08	Computed from Table 1 (BCG not yet DTP vs. Unvaccinated)
		Girls	MRR (unadjusted)	0.65	0.21	2.02	Computed from Table 1 (BCG not yet DTP vs. Unvaccinated)

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

2 BGC: ESTIMATES FOR DIFFERENT AGES

ARTICLE GROUP	REFID	AGE AT VACCINATION	FOLLOW-UP	ES	LCI	UCI	DETAILS

Bangladesh A	#797	vaccination at 0-2 months	age 0-60 months	0.2	0.07	0.54	Extracted from Table 6
	#797	vaccination at 2-6 months		0.59	0.46	0.75	Extracted from Table 6
	#797	vaccination at 6-12 months		1.12	0.68	1.8	Extracted from Table 6
	#797	vaccination at 12-60 months		1.36	0.86	2.14	Extracted from Table 6
Guinea-Bissau D	#2726	age 0-1 months at first visit*	6-month follow-up	0.57	0.35	0.94	Computed from counts on Table 3 (Vaccinated vs. Not vaccinated)
	#2726	age 2-3 months at first visit*		0.65	0.4	1.06	Computed from counts on Table 3 (Vaccinated vs. Not vaccinated)
	#2726	age 4-6 months at first visit*		1.12	0.66	1.9	Computed from counts on Table 3 (Vaccinated vs. Not vaccinated)
Guinea-Bissau I	#839	vaccination at first week	up to 6 months	0.11	0.03	0.5	Computed from rates on Table 2 (vaccinated in 1st wk vs unvaccinated, at 6 mo of age)
	#839	vaccination after first week	up to 6 months	0.3	0.14	0.65	Computed from rates on Table 2 for the comparison BCG vs. no BCG at 6 mo of age, substracting the deaths (2) and person-years (54.4) for children who got vaccinated in the first week
Papua New Guinea	#784	vaccination before 2 months (for most)	age 1-5 months	0.17	0.09	0.34	Extracted from Table 5(a)
	#784		age 6-11 months	0.88	0.31	2.51	Extracted from Table 5(a)
	#784		age 12-23 months	1.78	0.36	8.88	Extracted from Table 5(a)

3 BCG: ESTIMATES STRATIFIED BY VITAMIN A SUPPLEMENTATION (VAS)

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
Guinea-Bissau A	#339	VAS interaction	Interaction effect	1.31	0.41	4.22	Computed from Table 4 (from the estimates for children allocated to "early BCG" vs. children allocated to "no early BCG")
India A	#741	No VAS	Hazard ratio (unadjusted)	0.47	0.27	0.82	Computed from Table 4 (a weighted average of the estimates for males and females who received placebo and BCG, but not DTP, was calculated)
		VAS	Hazard ratio (unadjusted)	0.41	0.23	0.73	Computed from Table 4 (a weighted average of the estimates for males and females who received VAS and BCG, but not DTP, was calculated)

ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

4 DTP: ESTIMATES STRATIFIED BY SEX

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
Bangladesh A	#9477	Boys	MRR (adjusted)	0.84	0.38	1.85	Extracted from Supplementary Table 1 for Males
		Girls	MRR (adjusted)	0.36	0.18	0.72	Extracted from Supplementary Table 1 for Females
Burkina Faso	#799	Boys	Risk Ratio (adjusted)	1.29	0.61	2.71	Computed from Table 4 (from the adjusted estimates of BCG+DTP vs. BCG for boys)*
		Girls	Risk Ratio (adjusted)	0.81	0.39	1.66	Computed from Table 4 (from the adjusted estimates of BCG+DTP vs. BCG for girls)*
Guinea-Bissau A	#25	Boys	MRR (adjusted)	2.48	0.61	10	Extracted from Table 3
		Girls	MRR (adjusted)	7.18	1.53	33.7	Extracted from Table 3
Guinea-Bissau D	#9466	Boys	Risk Ratio (adjusted)	1.45	0.81	2.59	Extracted from page 1
		Girls	Risk Ratio (adjusted)	2.31	1.16	4.59	Extracted from page 1
Guinea-Bissau E	#851	Boys	Risk Ratio (adjusted)	1.56	0.7	3.48	Extracted from page 377
		Girls	Risk Ratio (adjusted)	2.34	1.04	5.27	Extracted from page 377
Guinea-Bissau P	#2622	Boys	Risk Ratio (unadjusted)	0.21	0.01	3.34	Computed from rates on Table 2 (Vaccinated vs. unvaccinated, entry age 1.25-5 months)
		Girls	Risk Ratio (unadjusted)	2.33	0.14	39.2	Computed from rates on Table 2 (Vaccinated vs. unvaccinated, entry age 1.25-5 months)
India A	#741	Boys	Hazard Ratio (unadjusted)	1.04	0.4	2.69	Computed from Table 4J (from the estimates of BCG+DTP vs. BCG for boys)*
		Girls	Hazard Ratio (unadjusted)	2.52	1.04	6.09	Computed from Table 4K (from the estimates of BCG+DTP vs. BCG for girls)*
India G	#9463	Boys	MRR (unadjusted)	0.22	0.14	0.35	Computed from rates on Table 3 (DTPp exposed group vs. BCG exposed group at 6 weeks-8 months)
		Girls	MRR (unadjusted)	0.37	0.22	0.62	Computed from rates on Table 3 (DTPp exposed group vs. BCG exposed group at 6 weeks-8 months)
Malawi	#664	Boys	MRR (adjusted)	2.06	0.43	9.75	Extracted from Table 2B
		Girls	MRR (adjusted)	5.44	0.88	33.7	Extracted from Table 2B
Papua New Guinea	#784	Boys	MRR (unadjusted)	0.76	0.31	1.86	Computed from Table 3 (DTP after BCG-Male vs. BCG only-Male at 29 days-5 months)
		Girls	MRR (unadjusted)	0.5	0.13	2.01	Computed from Table 3 (DTP after BCG-Male vs. BCG only-Female at 29 days-5 months)
Philippines	#555	Boys	Hazard Ratio (adjusted)	0.85	0.25	2.87	Extracted from page 1025
		Girls	Hazard Ratio (adjusted)	0.96	0.26	5.15	Extracted from page 1025
Senegal D	#9433	Boys	MRR (unadjusted)	0.42	0.09	2.10	Computed from Table 1 (DTP1 vs. BCG not yet DTP)
		Girls	MRR (unadjusted)	3.55	0.92	17.6	Computed from Table 1 (DTP1 vs. BCG not yet DTP)

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.
* The effect was computed as a ratio between the two effects reported in the article, and the standard error was computed based on the methods described by Greenland and Longnecker[1].

5 DTP: ESTIMATES FOR DIFFERENT AGES

ARTICLE GROUP	REFID	AGE AT VACCINATION	FOLLOW-UP	ES	LCI	UCI	DETAILS
Bangladesh A	#797	vaccination at 1.5-9 months	age 1.5-9 months	0.76	0.67	0.88	Extracted from Table 2
	#797		age 9-60 months	0.77	0.67	0.88	Extracted from Table 5
Ghana A	#3294	vaccination at 6-35 months	4-month follow-up	2.39	0.82	6.99	Computed from adjusted estimates on Table 5 (DTP1-2, no MV vs. Health card: noDTP, noMV)
	#3294		24-month follow-up	1.64	0.81	3.3	Computed from adjusted estimates on Table 5 (DTP1-2, no MV vs. Health card: noDTP, noMV)
Guinea-Bissau D	#2726	age 1.5-3 months at first visit*	6-month follow-up	1.58	0.84	2.97	Computed from counts on Table 4 (Vaccinated vs. Not vaccinated, children who received BCG)
	#2726	age 4-6 months at first visit*		1.38	0.62	3.07	Computed from counts on Table 4 (Vaccinated vs. Not vaccinated, children who received BCG)
Guinea-Bissau E	#851	age 2-4 months at visit*	age 8 months	2.21	1.01	4.8	Computed from rates on the two first columns on the right of Table 1, grouping 2, 3 and 4 months)
	#851	age 5-6 months at visit*		0.47	0.21	1.09	Computed from rates on the two first columns on the right of Table 1, grouping 5 and 6 months)
	#851	age 7-8 months at visit*		0.78	0.28	2.16	Computed from rates on the two first columns on the right of Table 1, grouping 7 and 8 months)
Guinea-Bissau P	#2622	vaccination from 1.25 months	age 1.25-5 months	1.07	0.19	5.91	Computed from rates on Table 2 (combining boys and girls)
	#2622		age 6-20 months	1.63	0.39	6.85	Computed from rates on Table 2 (combining boys and girls)
Papua New Guinea	#784	vaccination before 3 months (for most)	age 1.5 months	0.48	0.22	1.09	Extracted from Table 6
	#784		age 6-11 months	0.26	0.05	1.3	Extracted from Table 6
	#784		age 12-23 months	0.45	0.22	0.91	Extracted from Table 6

[1] 1. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992; 135(11): 1301-9.

6 DTP: ESTIMATES STRATIFIED BY VITAMIN A SUPPLEMENTATION (VAS)

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
India A	#741	No VAS	Hazard ratio (unadjusted)	1.93	0.83	4.45	Computed from Table 4J in two steps: 1st Sex stratified estimates were obtained from the estimates for BCG+DTP vs. BCG presented on Table 4* 2nd A weighted average of the estimates for boys and girls was obtained, similar as described on the previous table.
		VAS	Hazard ratio (unadjusted)	1.41	0.53	3.73	

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.
* The effect was computed as a ratio between the two effects reported in the article, and the standard error was computed based on the methods described by Greenland and Longnecker.

7 MV: ESTIMATES STRATIFIED BY SEX

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
Ghana A	#3294	Boys	MRR (adjusted)	0.5	0.19	1.31	Extracted from Table 4
		Girls	MRR (adjusted)	0.52	0.22	1.23	Extracted from Table 4
Guinea-Bissau C	#1731	Boys	MRR (adjusted)	0.94	0.44	2.01	Extracted from Table 2
		Girls	MRR (adjusted)	0.46	0.19	1.11	Extracted from Table 2
Guinea-Bissau G	#9441	Boys	MRR (adjusted)	1.02	0.65	1.62	Extracted from Table 3
		Girls	MRR (adjusted)	0.5	0.32	0.78	Extracted from Table 3
Guinea-Bissau O	#6888	Boys	MRR (unadjusted)	0.76	0.22	2.64	Computed from rates on Table 2 (Standard group, Two vaccines vs. only one vaccine)
		Girls	MRR (unadjusted)	0.24	0.09	0.62	Computed from rates on Table 2 (Standard group, Two vaccines vs. only one vaccine)
Guinea-Bissau S	#2202	Boys	MRR (unadjusted)	1.01	0.52	1.96	Computed from rates on Table 1 (Follow-up to 9 mo of age, second two-dose trial, Early Measles Vaccine vs. IPV Control Group)
		Girls	MRR (unadjusted)	0.94	0.53	1.67	Computed from rates on Table 1 (Follow-up to 9 mo of age, second two-dose trial, Early Measles Vaccine vs. IPV Control Group)
India G	#9463	Boys	MRR (unadjusted)	0.42	0.18	0.98	Computed from rates on Table 3 (Measles V exposed group vs. DTPp exposed group at 9-15 months)
		Girls	MRR (unadjusted)	0.4	0.2	0.82	Computed from rates on Table 3 (Measles V exposed group vs. DTPp exposed group at 9-15 months)
Malawi	#664	Boys	MRR (adjusted)	0.62	0.22	1.8	Extracted from Table 2A
		Girls	MRR (adjusted)	0.23	0.04	1.27	Extracted from Table 2A
Senegal A	#6904	Boys	MRR (unadjusted)	1.28	0.85	1.94	Computed from rates on Table 2 (1985-1986, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)
		Girls	MRR (unadjusted)	0.69	0.41	1.17	Computed from rates on Table 2 (1985-1986, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)

Senegal B	#6904	Boys	MRR (unadjusted)	0.86	0.44	1.67	Computed from rates on Table 2 (1987-1988, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)
		Girls	MRR (unadjusted)	0.51	0.24	1.05	Computed from rates on Table 2 (1987-1988, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)
Senegal C	#6904	Boys	MRR (unadjusted)	0.43	0.22	0.85	Computed from rates on Table 2 (1989-1990, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)
		Girls	MRR (unadjusted)	0.61	0.23	1.61	Computed from rates on Table 2 (1989-1990, 9-23 months, Schwarz standard vaccinated vs. Unvaccinated)
Senegal D	#9433	Boys	MRR (unadjusted)	0.85	0.32	2.25	Computed from Table 1 (MV$ vs. combination of DTP1, DTP2 & DTP3 from the subgroup who received BCG first)
		Girls	MRR (unadjusted)	0.35	0.12	1.03	Computed from Table 1 (MV$ vs. combination of DTP1, DTP2 & DTP3 from the subgroup who received BCG first)

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

8 MV: ESTIMATES FOR DIFFERENT AGES

ARTICLE GROUP	REFID	AGE AT VACCINATION	FOLLOW-UP	ES	LCI	UCI	DETAILS
Benin	#9372	vaccination up to 12 months	age up to 35 months	0.36	0.16	0.81	Extracted from Table 2
	#9372	vaccination after 12 months		1.02	0.43	2.41	Extracted from Table 2
DR Congo	#7108	vaccination at 8-12 months	age 7-21 months	0.29	0.09	0.98	Computed from rates on Table I (Group IV vs. Group 2)
	#7108		age 7-35 months	0.52	0.21	1.29	Computed from rates on Table I (Group IV vs. Group 2)
Ghana B	#7190	vaccination at 9 months (for most)	age 9-11 months	0.78	0.43	1.41	Extracted from Table 3
	#7190		age 12-23 months	0.35	0.26	0.47	Extracted from Table 3
	#7190		age 24-59 months	1.79	0.83	3.87	Extracted from Table 3
Guinea-Bissau D	#2726	age 7-8 months at first visit*	6-month follow-up	0.76	0.24	2.38	Computed from counts on Table 5 (Vaccinated vs. Not vaccinated)
	#2726	age 9-11 months at first visit*		0.43	0.22	0.84	Computed from counts on Table 5 (Vaccinated vs. Not vaccinated)
	#2726	age 12-13 months at first visit*		0.65	0.19	2.21	Computed from counts on Table 5 (Vaccinated vs. Not vaccinated)
Guinea-Bissau L	#8668	vaccination from 6	age 6-8 months	0.27	0.05	1.4	Computed from counts on Table II for the comparison of children

		months					vaccinated against measles (combining measles and no measles groups) vs. not vaccinated
	#8668		age 9-11 months	0.5	0.16	1.56	Computed from counts on Table II for the comparison of children vaccinated against measles (combining measles and no measles groups) vs. not vaccinated
	#8668		age 12-23 months	0.69	0.18	2.57	Computed from counts on Table II for the comparison of children vaccinated against measles (combining measles and no measles groups) vs. not vaccinated
	#8668		age 24-35 months	0.38	0.02	8.89	Computed from counts on Table II for the comparison of children vaccinated against measles (combining measles and no measles groups) vs. not vaccinated
India G	#9463	vaccination at 9 months (for most)	age 9-15 months	0.41	0.24	0.7	Computed from rates on Table 3 (Measles V exposed group vs. DTPp exposed group, combining boys and girls)
	#9463		age 9-36 months	0.52	0.32	0.85	Computed from rates on Table 3 (Measles V exposed group vs. DTPp exposed group, combining boys and girls)
Malawi	#664	median age at vaccination was 10.8 months	age 9-11 months	0.15	0.02	1.21	Computed from rates on Table 1 (Measles vaccine vs. No vaccine, combining F and M, adding .5 to the death counts for the MRR to be computable and modifying the person-year times accordingly)
	#664		age 12-17 months	0.19	0.01	3.34	Computed from rates on Table 1 (Measles vaccine vs. No vaccine, combining F and M, adding .5 to the death counts for the MRR to be computable and modifying the person-year times accordingly)
	#664		age 18-35 months	0.21	0.03	1.58	Computed from rates on Table 1 (Measles vaccine vs. No vaccine, combining F and M)
	#664		age 36-59 months	0.19	0.01	3.22	Computed from rates on Table 1 (Measles vaccine vs. No vaccine, combining F and M, adding .5 to the death counts for the MRR to be computable and modifying the person-year times accordingly)
Papua New Guinea	#784	vaccination at 9 months (for most)	age 1-5 months	2.68	0.34	21.18	Extracted from Table 5(a)
	#784		age 6-11 months	0.42	0.17	1.01	Extracted from Table 5(a)
	#784		age 12-23 months	0.95	0.3	3.05	Extracted from Table 5(a)
Senegal A	#6904	vaccination at 9-10 months	age 9-23 months	0.99	0.72	1.37	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1985-1986)
	#6904		age 9-60 months	0.75	0.59	0.94	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1985-1986)
Senegal B	#6904	vaccination at 9-10 months	age 9-23 months	0.68	0.42	1.1	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1987-1988)
	#6904		age 9-60 months	0.67	0.46	0.98	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1987-1988)

Senegal C	#6904	vaccination at 9-10 months	age 9-23 months	0.49	0.28	0.85	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1989-1990)
	#6904		age 9-60 months	0.6	0.37	0.97	Computed from rates on Table 2 (Schwarz standard vaccinated vs. Unvaccinated,combining boys and girls, 1989-1990)

9 MV: ESTIMATES STRATIFIED BY VITAMIN A SUPPLEMENTATION (VAS)

ARTICLE GROUP	REFID	SUBGROUP	EFFECT INDEX	ES	LCI	UCI	DETAILS
Guinea-Bissau A	#9436	No VAS	MRR (unadjusted)	0.08	0	1.33	Computed from rates on Table 3, comparing early MV vs. no early MV at 4.5-8 months for children (males+females) who were allocated to Placebo
		VAS	MRR (unadjusted)	1.13	0.54	2.38	Computed from rates on Table 3, comparing early MV vs. no early MV at 4.5-8 months for children (males+females) who were allocated to NVAS
Guinea-Bissau G	#78	No VAS	MRR (unadjusted)	4.32	0.87	21.4	Computed from rates on Table 3 (DTP+MV vs. DTP in children allocated to No VAS)
		VAS	MRR (unadjusted)	0.81	0.11	6.04	Computed from rates on Table 3 (DTP+MV vs. DTP in children allocated to VAS)
Guinea-Bissau H	#2543	No VAS	Risk Ratio (unadjusted)	7.19	0.38	137	Computed from counts on page 825 (MV vs. IPV at 6 months for children who received placebo)
		VAS	Risk Ratio (unadjusted)	0.14	0.01	2.65	Computed from counts on page 825 (MV vs. IPV at 6 months for children who received VAS)

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

10 VACCINATION SEQUENCES: BCG AND DTP

ARTICLE GROUP	REFID	GROUP1	GROUP2	EFFECT INDEX	ES	LCI	UCI	DETAILS
Bangladesh A	#9477	BCG=DTP	BCG<DTP	MRR (adjusted)	0.56	0.33	0.97	Computed from Table 3 (inverse of the estimate for BCG<DTP1 vs. BCG=DTP1, that is, 1/1.78)
Bangladesh A	#9477	BCG>DTP	BCG<DTP	MRR (adjusted)	0.88	0.48	1.63	Computed from Table 3 (from the estimates of BCG>DTP1 vs. BCG<DTP1)**
India E	#8996	BCG=DTP	BCG<DTP	MRR (unadjusted)	0.23	0.03	1.83	Computed from rates on Table 4 (BCG and DTP simultaneously vs. DTP after BCG)
India E	#8996	BCG>DTP	BCG<DTP	MRR (unadjusted)	0.13	0.01	2.22	Computed from rates on Table 4 (BCG after DTP vs. DTP after BCG)
Papua New Guinea	#784	BCG>DTP BCG=DTP	BCG<DTP	MRR (unadjusted)	2.01	0.89	4.55	Computed from rates on Table 3 (DTP before/with BCG vs. DTP after BCG, at 29 days-5 months, combining Male and Female rates)
Papua New Guinea	#784	BCG>DTP	BCG<DTP	MRR (unadjusted)	0.62	0.24	1.64	Computed from rates on Table 3 (DTP before/with BCG vs. DTP after BCG, at 6-11 months, combining Male and Female rates)

		BCG=DTP						
Senegal D	#9433	BCG=DTP	BCG<DTP	MRR (adjusted)	0.51	0.25	1.07	Computed from Table 1 (from the adjusted estimates of BCG=DTP1 vs. DTP1)*
Senegal D	#9433	BCG>DTP	BCG<DTP	MRR (adjusted)	0.52	0.07	4.05	Computed from Table 1 (from the adjusted estimates of BCG>DTP1 vs. DTP1)*

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

* The effect was computed as a ratio between the two effects reported in the article, and the standard error was computed based on the methods described by Greenland and Longnecker.

** The estimates for BCG>DTP1 and BCG<DTP1 were only indirectly linked on the table by the reference group BCG=DTP1, which was compared with BCG and with DTP1. In order to get an adjusted effect, the following strategy was implemented:

I. The product of the estimates for BCG>DTP1 vs. DTP1 and DTP1 vs. BCG=DTP1 was computed, that is, 1.07 x 1.47 = 1.5729.

II. The product of the estimates for BCG<DTP1 vs. BCG and BCG vs. BCG=DTP1 was computed, that is, 0.52 x 3.44 = 1.7888.

III. The adjusted effect for BCG>DTP1 vs. BCG<DTP1 is the ratio between the two values previously obtained, 1.5729/1.7888 = 0.88.

IV. The standard error was computed based on the methods described by Greenland and Longnecker.

11 VACCINATION SEQUENCES: DTP AND MV

ARTICLE GROUP	REFID	GROUP1	GROUP2	EFFECT INDEX	ES	LCI	UCI	DETAILS
Guinea-Bissau G	#9442	DTP=MV	DTP<MV	MRR (adjusted)	3.35	1.25	9.01	Extracted from Table 2
Guinea-Bissau Q	#2218	DTP>MV	DTP<MV	Risk Ratio (unadjusted)	1.52	0.71	3.21	Computed from rates on Table 3 (DTP after MV vs. DTP before MV, combining boys and girls)
Guinea-Bissau Q	#2218	DTP=MV	DTP<MV	Risk Ratio (unadjusted)	1.95	1.12	3.42	Computed from rates on Table 3 (DTP=MV vs. DTP before MV, combining boys and girls)
India E	#8996	DTP=MV	DTP<MV	MRR (adjusted)	4.77	0.33	70.2	Extracted from Table 6
India E	#8996	DTP>MV	DTP<MV	MRR (adjusted)	15.9	2.12	119	Extracted from Table 6
Malawi	#664	DTP=MV	DTP<MV	MRR (adjusted)	5.27	1.11	25	Extracted from page 724
Senegal D	#9433	DTP=MV	DTP<MV	MRR (adjusted)	1.96	0.95	4.04	Computed from Table 1 (from the adjusted estimates of MV=DTP vs. MV$)*
Senegal D	#9433	DTP>MV	DTP<MV	MRR (adjusted)	2.4	1	5.75	Computed from Table 1 (from the adjusted estimates of MV<DTP vs. MV$)*

MRR: Mortality Rate Ratio; ES: effect estimate; LCI: lower bound of the confidence interval; UCI: upper bound of the confidence interval.

* The effect was computed as a ratio between the two effects reported in the article, and the standard error was computed based on the methods described by Greenland and Longnecker.